BioWorld

March 19, 2007

Tracon Licenses D93 Antibody From Micromet

In a deal worth up to $100 million, Micromet Inc. licensed the preclinical anti-angiogenesis monoclonal antibody D93 to privately held Tracon Pharmaceuticals Inc. (BioWorld Today) Read More

Pfizer, Biogen Idec Launch Incubators To Build Pipelines

Alexion Gets FDA Nod For Soliris; First Drug For PNH

Trimeris Taking Back Rights To Next HIV Fusion Inhibitor

House Subcommittee Advances Genetic Discrimination Measure

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 17, 2025.

Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

BioWorld

During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...

23andme founder-led group outbids Regeneron for company

BioWorld

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...

Elevidys’ second liver death hits Sarepta, sends DMD ripples

BioWorld

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...